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Bartonella quintana, a pathogen that is restricted to
human hosts and louse vectors, was first characterized as
the agent of trench fever. The disease was described in
1915 on the basis of natural and experimental infections in
soldiers. It is now recognized as a reemerging pathogen
among homeless populations in cities in the United States
and Europe and is responsible for a wide spectrum of con-
ditions, including chronic bacteremia, endocarditis, and
bacillary angiomatosis. Diagnosis is based on serologic
analysis, culture, and molecular biology. Recent character-
ization of its genome allowed the development of modern
diagnosis and typing methods. Guidelines for the treatment
of B. quintana infections are presented.
T
rench fever, the first clinical manifestation attributed
to Bartonella quintana, affected an estimated >1 mil-
lion people during World War I (1,2). The name “trench
fever” was mentioned for the first time in 1915 (3,4). In
1916, McNee et al. described 2 types of the disease (5).
The first was characterized by a sudden onset of headache,
dizziness, pain in the shins, and elevated temperature
(39°C–40°C). Between days 3 and 7, temperature would
suddenly drop to normal or subnormal. Thereafter, temper-
ature rose sharply before falling again. The second mani-
festation of the disease was characterized by a shorter
initial period and frequent relapses. In 1919, 200 consecu-
tive cases were recorded by Byam et al., and transmission
by human body lice was demonstrated, but the nature of
the trench fever agent was still unknown (4).
Trench fever was precisely described based on experi-
mental infections in volunteer soldiers (4). The first exper-
iments consisted of transmitting whole blood from typical
cases to volunteers, which reproduced natural infection.
Byam confirmed in 1919 the others’ work, showing that
“rickettsia bodies” were present in lice, their excreta, and
their guts when they were collected from trench fever
patients. In 1949, Kostrzewski precisely described trench
fever after an accidental epidemic spread among louse-
feeders in laboratories that produced typhus vaccine (6).
Of 104 persons who worked with lice, 90 contracted symp-
tomatic trench fever, and 5 were asymptomatic carriers.
Three different courses of trench fever were described by
Kostrzewski: the classic relapsing form associated with
shin pain, headaches, and dizziness; the typhoidal form
characterized by a prolonged fever, splenomegaly, and
rash; and the abortive form, characterized by a brief, less
intense course.
After World War I, the incidence of trench fever
decreased dramatically, but during World War II, epi-
demics were again reported (6). More recently, reports
have indicated the reemergence of B. quintana infections
among the homeless population in cities in both Europe
and the United States (7,8). Major predisposing factors for
new B. quintana infections include poor living conditions
and chronic alcoholism (8). Epidemics of trench fever
were also recently reported in particular conditions, such
as in refugee camps in Burundi in 1997, where pediculosis
was prevalent (1).
The Bacterium
Taxonomy
When trench fever was first described in 1915, its etio-
logic agent was called Rickettsia quintana or R. volhynica
(6). At the same time, other names were also proposed, i.e.,
R. pediculi, R. weigli, and R. rocha-limae (1). The 1984
edition of Bergey’s Manual of Systematic Bacteriology
combines  Rickettsiaceae,  Bartonellaceae, and
Anaplasmataceae families into the Rickettsiales order. R.
quintana was classified in the genus Rochalimaea, tribe
Rickettsiae, family Rickettsiaceae. In 1993, Brenner et al.
proposed unifying the genera Bartonella and Rochalimaea
(9). They also proposed removing the unified genus
Bartonella from the Rickettsiales order. The new unified
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tana, B. vinsonii, B. henselae, and B. elizabethae. In 1995,
Birtles et al. proposed unifying the Bartonella and
Grahamella genera (10), and the 2 established Grahamella
species,  Grahamella talpae and  G. peromysci, were
renamed as Bartonella species. Birtles et al. also described
3 new species within Bartonella: B. grahami, B. taylorii,
and B. doshiae (3,10).
Characteristics
B. quintana is a facultative, intracellular, gram-negative
rod belonging to the α2 subgroup of proteobacteria (3). It
is a short rod, 0.3–0.5 µm wide and 1–1.7 µm long.
Catalase and oxidase reactions are negative. The bacterium
can be grown on axenic media and cocultivated in cell cul-
ture (3,11). When grown on blood agar, rough colonies
embedded in the agar are obtained after 12 to 14 days, but
prolonged incubation may be necessary, up to 45 days for
primary isolation. Subcultures reduce the time to obtain
colonies to only 3–5 days (11). Humans are the reservoir of
the bacterium (12), and the human body louse, Pediculus
humanus corporis, is its usual vector (1). B. quintana is
located in erythrocytes during asymptomatic bacteremia
(13) and has been observed in erythroblasts in bone mar-
row in bacteremic patients (14). The bacterium has a tro-
pism for endothelial cells, leading to angioproliferative
lesions, as observed in bacillary angiomatosis (15).
Genome
The 1.6-Mb genome of B. quintana has recently been
sequenced and was found to be a derivate of the larger 1.9-
Mb genome of B. henselae; the main difference between
the species is the absence of genomic islands in B. quin-
tana (16). Both B. quintana and B. henselae genomes are
shortened versions of chromosome I from Brucella
melitensis, a phylogenetically highly related bacterium
(16). The comparison of B. henselae and  B. quintana
genome and the specialization of the latter to its human
reservoir and louse vector suggest that use of host-restrict-
ed vectors is associated with accelerated rates of genome
degradation (16).
Epidemiologic Features and Natural History
Transmission
B. quintana is transmitted by the human body louse, P.
humanus corporis (Figure 1), which lives in clothes
(Figure 2) and is associated with poverty, lack of hygiene,
and cold weather. In our cohort of 930 homeless persons,
lice infestation was present in 22% and was associated
with hypereosinophilia (17). Pediculosis (lice infestation)
is transmitted by contact with clothes or bedding, is preva-
lent in the homeless population. B. quintana multiplies in
the louse’s intestine and is transmitted to humans by feces
through altered skin (1). Body lice usually feed 5 times a
day and inject their bites with biological proteins, includ-
ing an anesthetic that provokes an allergic reaction and
leads to pruritus and scratching (Figure 3), which facili-
tates the fecal transmission of B. quintana, and persistent
B. quintana bacteremia facilitates its spread by lice (12).
Body lice are probably not the only vectors of B. quintana.
The bacterium was recently detected in cat fleas (18) and
in cat dental pulp (19), which suggests bacteremia in cats,
and has been isolated in a patient who owned a cat and
sought treatment for chronic adenopathy (20). These data
suggest a transmission mode similar to that observed for B.
henselae in cat-scratch disease.
Natural History of B. quintana Infection
After trench fever (which corresponds to the primary
infection) resolves, chronic bacteremia will develop in
some patients (7). Overproduction of interleukin-10 could
be partially responsible for persistence of bacteremia. The
link between chronic bacteremia and B. quintana endo-
carditis has not been clearly shown, but it likely exists.
Chronic asymptomatic bacteremia in humans indicates
that they may be the natural reservoir of B. quintana (12),
as this condition occurs with other Bartonella species in
their reservoirs, i.e., B. henselae in cats, B. alsatica in rab-
bits, and B. tribocorum in rats. However, other reservoirs
should be investigated for B. quintana because the bacteri-
um has been detected in cat fleas (18), cat teeth (19), and
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Figure 1. Pediculus humanus corporis, the human body louse,
viewed with electron microscope at magnification ×120.monkey fleas (unpub. data). Recently, an animal model of
B. quintana infection in rhesus macaques has been devel-
oped to reproduce the prolonged bacteremia that is
observed in humans (21).
Surveys in Homeless Shelters
A substantial seroprevalence of B. quintana has been
reported in France (7) and the United States (22). An epi-
demiologic survey conducted in emergency rooms of the
University Hospital in Marseilles, France, showed that
30% of 71 tested homeless persons had antibody titers
against B. quintana and that 14% were bacteremic (7). We
found that 50 (5.4%) of 930 nonhospitalized, homeless
persons tested during 4 years (2000–2003) were bac-
teremic (17).
Clinical Manifestations
Trench Fever
Trench fever is characterized by attacks of fever that
last 1–3 days; are associated with headache, shin pain, and
dizziness; and recur every 4–6 days (2,23), although each
succeeding attack is usually less severe. The incubation
period typically varies from 15 to 25 days but may be
reduced to 6 days in experimental infections (3,4).
Although trench fever often results in prolonged disability,
no deaths have been reported (1,3).
Chronic Bacteremia
Persistent bacteremia has long been associated with B.
quintana infection (2,4). Kostrzewski showed that B. quin-
tana was present in the blood of trench fever patients up to
8 years after initial infection (6). More recently, asympto-
matic and prolonged bacteremia was confirmed in 16 of 42
patients with positive blood cultures (12). Chronic
bacteremia persisted for 78 weeks in 1 of those patients,
for 53 and 17 weeks in 2 other patients, and for 1 to 8
weeks in the remaining 13. Intermittent bacteremia was
also observed over periods of 4 to 58 weeks.
Endocarditis
Cases and series of Bartonella endocarditis have been
widely reported (2,24), including a report of 48 cases, 38 of
B. quintana infection, and 10 of B. henselae infection (24).
Patients appeared to have chronic, blood culture–negative
endocarditis; fever was usually present (90%), a vegetation
was usually observed on echocardiograph (90%), and
>90% of patients required valvular surgery. B. quintana
endocarditis mostly develops in persons without any previ-
ous valvular injuries; known risk factors are alcoholism,
homelessness, and body lice infestation. B. henselae endo-
carditis patients frequently have a previous valvulopathy,
and disease is associated with cat bites or scratches and cat
flea exposure (24). Treatment and outcome of Bartonella
endocarditis were examined on the basis of 101 cases (25).
Patients who received an aminoglycoside were more likely
to fully recover, and those treated with aminoglycosides for
>14 days were more likely to survive than those treated for
a shorter duration. Of the 101 patients with Bartonella
endocarditis, 12 (11.9%) died despite antimicrobial drug
therapy and valvular surgery, 10 of acute heart failure and
2 of multiorgan failure (25). 
Bacillary Angiomatosis
Bacillary angiomatosis was first described early in the
HIV epidemic (2,26). It is a proliferative vascular disease
recognized in both immunocompetent and immunodefi-
cient patients (mostly HIV-infected persons) (3,27).  B.
quintana and B. henselae are the 2 etiologic agents (26).
Various organs may be affected, including the liver, spleen,
bone marrow, and lymph nodes, but the skin is most often
involved (3). Cutaneous lesions may be solitary or multi-
ple and may bleed profusely when punctured. They may be
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Figure 2. Human body lice in clothes.
Figure 3. Lesions from scratching induced by body lice infestation.superficial, dermal, or subcutaneous. Superficial lesions
may be red, purple, or colorless. Deep lesions are not usu-
ally colored and are either mobile or fixed to underlying
structures. The oral, anal, and gastrointestinal mucosa may
also be involved (3). Molecular epidemiologic features of
Bartonella infections in HIV-infected patients with bacil-
lary angiomatosis were investigated (26); bone lesions and
subcutaneous masses were associated with B. quintana,
whereas hepatic peliosis and lymph node lesions were
associated with B. henselae. Bacillary angiomatosis may
be life-threatening in untreated patients.
Lymphadenopathy
B. quintana has been reported to cause lymphadenopa-
thy. A 30-year-old woman with isolated chronic, afebrile,
cervical, and mediastinal adenopathy was the first reported
patient (20). Histologic examination of the cervical lymph
node showed a granulomatous reaction, and B. quintana
was isolated from blood cultures. A second case was later
reported in a hemodialysis patient with Sjögren syndrome
who had mediastinal lymphadenopathies and secondary
pancytopenia (28). B. quintana was isolated from a bone
marrow biopsy specimen, and the bacterium was identified
by using molecular biologic methods. His serum showed
an antibody titer of 1:50 against B. quintana. In 2003, a
coinfection with B. quintana and Mycobacterium tubercu-
losis was reported in an HIV-infected patient with supra-
clavicular inflammatory lymphadenitis. The 2
microorganisms were isolated from lymph nodes (29).
Diagnosis
Serologic Tests
Serologic testing is the most widely used method to
diagnose  Bartonella infection. Indirect immunofluores-
cence is the reference method. Variability in antibody titers
may occur when different methods of antigen preparation
are used for the assay. Moreover, cross-reactions have been
reported with Coxiella burnetii and Chlamydia pneumoni-
ae (1,3). Western blot and cross-adsorption resolve this
problem and can be used to determine the species involved
(Figure 4) (30). On indirect immunofluorescence,
immunoglobulin G titers >1:50 indicate Bartonella infec-
tion, and titers >1:800 predict endocarditis (31).
Culture
B. quintana was first cultivated in axenic media by
Vinson in the early 1960s (32). To date, the most widely
used methods for isolation are direct plating onto solid
media, blood culture in broth, and cocultivation in cell cul-
ture (11). From 1993 to 1998, we correlated the results of
Bartonella-positive cultures with the type of sample, the
culture procedure, and polymerase chain reaction (PCR)–
based genomic detection (11). During this period, we
received 2,043 samples of Bartonella species for culture
and obtained 72 isolates of B. quintana. The most efficient
culture method in patients with endocarditis was to subcul-
ture blood culture broth into shell vials. For samples from
homeless patients with B. quintana bacteremia, subcultur-
ing blood culture broth onto agar was more efficient than
direct blood plating (11). Lysis centrifugation has been
shown to enhance the recovery of Bartonella species as
well as sample congelation from blood. Primary isolates
are typically obtained after 12–14 days, although an incu-
bation period of up to 45 days may be necessary (11).
Molecular Biology
Bartonella species can be detected from blood and tis-
sues by using PCR. Various tissues may be used, including
lymph node, cardiac valve, skin, and liver. Although fresh
tissues are more convenient, formalin-fixed, paraffin-
embedded tissues may be used for PCR-based assay as
well. Using universal primers to amplify the 16S rRNA
gene is not a convenient method for diagnosing Bartonella
infection to the species level because the 16S rRNA genes
of  Bartonella species are >97.8% similar. New targets
have been used to detect Bartonella species with a PCR-
based assay (see online Appendix Table available from
http://www.cdc.gov/ncidod/EID/vol12no02/05-0874_
app.htm) (33).
Immunohistochemistry and Immunofluorescence
Immunohistochemistry is a convenient tool for detect-
ing  B. quintana in tissues. Positive detection has been
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Figure 4. Western blot and cross-adsorption results in a patient
with  Bartonella quintana endocarditis. A) Nonadsorbed. B)
Adsorbed with B. quintana. C) Adsorbed with B. henselae. Lane 1,
B. quintana; lane 2, B. henselae; lane 3, B. elizabethae; lane 4, B.
vinsonii subsp.  Berkhoffi; lane 5, B. vinsonii subsp.  Arupensis.
Before adsorption (A), antibodies are detected against all species
(1, 2, 3, 4, and 5). After adsorption with B. quintana antigen (B), all
antibodies disappear. After adsorption with B. henselae antigen
(C), antibodies against B. quintana (1) persist. This reaction shows
B. quintana infection.reported in valvular tissue (Figure 5) (34) and in skin biop-
sies of patients with bacillary angiomatosis (35). On
immunohistochemical tests, Bartonella species are
observed in proliferative endothelial cells localized in the
upper reticular dermis in patients with bacillary
angiomatosis (35). In patients with Bartonella endocardi-
tis, clusters of bacteria, mainly in the valvular vegetation,
occupy an extracellular location in the fibrin deposits (34).
B. quintana can be detected in erythrocytes by using
immunofluorescence (13). The bacterium is observed in
thin blood smears from fresh blood fixed with methanol
and stained with mouse monoclonal antibody (13). The
intraerythrocytic location of B. quintana can be confirmed
by using confocal microscopy (Figure 6) (13).
What Diagnostic Modality To Choose
Serologic testing and blood culture should be per-
formed as described above when B. quintana infection is
suspected, regardless of the clinical signs and symptoms.
When endocarditis is suspected, culture, immunohisto-
chemical tests, and PCR should be performed on the car-
diac valve when available. When bacillary angiomatosis is
suspected, culture, immunohistochemical tests, and PCR
may be performed on a skin biopsy specimen.
Typing
Pulsed-field Gel Electrophoresis (PFGE)
Until recently, the only available method for typing B.
quintana was PFGE, which allowed defining a specific
pattern for each of 7 tested isolates (36). However, the
PFGE profile does not correlate with that of the
sequenced-based typing method; variability in PFGE pat-
terns could be explained by frequent genome rearrange-
ments in B. quintana (37). This finding was supported by
the fact that the PFGE profile of 1 strain was modified
after 9 subcultures while the profile from sequence-based
typing remained identical (37), which showed that this
method was unreliable in assessing epidemiologic aspects
of B. quintana.
Multispacer Typing
Recently, we proposed a new typing method for B.
quintana, multispacer typing (MST) (37). This method,
first used for Yersinia pestis (38), is based on comparing
spacers, i.e., intergenic zones. Surprisingly, MST allowed
us to determine only 5 different sequence types among B.
quintana isolates. The finding of few sequence polymor-
phisms in the noncoding DNA of B. quintana agrees with
findings from a previous study in which 16S–23S spacer
sequencing allowed a specific sequence of each of the test-
ed B. henselae isolates to be identified, while only 2 differ-
ent types were identified for B. quintana (36). As B.
quintana is a genomic derivate of B. henselae (16), its
oligoclonality could have been caused by a very recent
adaptation to its unique human host and louse vector.
Treatment
Pediculosis
Pediculosis can be treated with insecticides, i.e., treat-
ing all clothing with 10% DDT, 1% malathion, or 1% per-
methrin dust (1). Because body lice live in clothing, lay
their eggs in clothing, and only visit human skin to feed,
the patient’s body does not need to be deloused. Boiling
infested clothes is also efficient (1). Changing a person’s
clothing, including underwear, is the simplest method for
delousing, but it is, however, not always practical (1).
Recently, oral agents have been evaluated, and ivermectin
has been efficient in delousing homeless persons in shel-
ters, without other measures (39). Bedding at shelters is a
major source of infestation and should be treated with
insecticides or by boiling the sheets. 
Antimicrobial Drug Susceptibility of B. quintana
Evaluation of susceptibilities to antimicrobial drugs has
been performed in both axenic media and cell culture.
Bacteria of the genus Bartonella are susceptible to a wide
range of agents, including penicillins, cephalosporins,
aminoglycosides, chloramphenicol, tetracyclines, macro-
lides, rifampin, fluoroquinolones, and cotrimoxazole (40).
However, only aminoglycosides have a bactericidal effect.
MICs correlate poorly with the in vivo efficacies of antimi-
crobial drugs in patients with B. quintana infection, and
this discrepancy may be explained by the lack of bacterici-
dal effect of most compounds and by sequestration of the
bacterium in erythrocytes (40).
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Figure 5. Immunohistochemical demonstration of Bartonella sp. in
a cardiac valve of a patient with endocarditis. Magnification ×400.Chronic Bacteremia
In 2003, a randomized trial showed that doxycycline in
combination with gentamicin was effective in treating
chronic bacteremia. Treatment was given as follows: doxy-
cycline 200 mg/day in 1 oral daily dose for 28 days com-
bined with gentamicin 3 mg/kg/day in 1 intravenous daily
dose for 14 days (40). This treatment is efficient at the
individual level, but B. quintana remains endemic in the
homeless persons in shelters in Marseilles, France,
although bacteremic persons have been treated for 4 years
(17). Considering the poor adherence of homeless persons
to medical care and treatment, a 1-month treatment,
including 14 days of intravenous treatment, is difficult to
manage in this population. Shorter durations should be
evaluated in the future.
Endocarditis
The efficiency of antimicrobial drugs to treat
Bartonella endocarditis has recently been evaluated
(25,40). Patients receiving an aminoglycoside are more
likely to fully recover (p = 0.02), and those treated with
aminoglycosides for >14 days are more likely to survive
than those who undergo therapy of shorter duration (p =
0.02) (25). The recommended treatment for B. quintana
endocarditis is as follows: doxycycline 100 mg 2×/day
orally for 6 weeks in combination with gentamicin 3
mg/kg/day in 1 intravenous daily dose for 14 days (40).
Bacillary Angiomatosis
Drug treatment of bacillary angiomatosis has not been
studied systematically to date, but erythromycin is report-
ed to be efficient and is currently the firstline agent of
choice (40). Doxycycline has also been recommended, and
successful treatment has been reported with ceftriaxone or
fluoroquinolones, but treatment with ciprofloxacin was
unsuccessful (40). The recommended treatment for bacil-
lary angiomatosis is erythromycin 500 mg 4×/day orally
for 3 months. In patients with a contraindication to
macrolides, doxycycline 100 mg 2×/day orally for 3
months should be considered (40). The dramatic efficien-
cy of erythromycin in bacillary angiomatosis is linked to
its antiangiogenic effect, rather than to its antimicrobial
effect (15).
Conclusion
B. quintana infection has long been disconcerting for
physicians and researchers. The uncommon quintan fever
has been a subject of medical curiosity since 1915, and its
clinical course and pathologic features have been under-
stood only after numerous experimental infections in vol-
unteers. The clinical spectrum of B. quintana infection
includes various manifestations such as bacillary
angiomatosis and endocarditis. Treatment of these infec-
tions has also been debated and has recently been codified.
To date, some points still remain to be elucidated. B. quin-
tana was thought to be strictly a human pathogen but was
recently detected in cat fleas and monkey fleas, which
reopens the debate on the existence of an animal reservoir.
The availability of the complete genome sequence of B.
quintana allows sequence-based typing, which has created
convenient tools for molecular epidemiology that are nec-
essary to determine the natural history of B. quintana
infection.
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